News
MyChesCo on MSN1h
ENHERTU plus Pertuzumab Shows Significant Progress in First-Line Treatment for HER2-Positive Breast CancerThe Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® ...
Development of a breakthrough vaccine researchers say could eradicate breast cancer by 2030 wrapped up phase one of its clinical trial this week, with more than 75% of women showing a strong immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback